Sino Biopharm (1177) Stock Price, Fundamentals & Analysis

What 1177 does

Sino Biopharm (1177) is a stock listed on the Hong Kong Stock Exchange stocks that operates as a research and development pharmaceutical conglomerate in the People's Republic of China. It functions as an investment holding company structured around three segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others. The company's portfolio spans oncology treatments — including anlotinib hydrochloride capsules under the Focus V brand and penpulimab injection under the Annike brand — as well as liver disease medications such as magnesium isoglycyrrhizinate injection under the Tianqing Ganmei brand and entecavir dispersible tablets under the Runzhong brand, alongside respiratory system medicines. Within the Healthcare sector and the Biotechnology industry, Sino Biopharm is a large-cap presence with 22,838 employees and headquarters in Wan Chai, Hong Kong. It is a peer to companies like WuXi Biologics (2269) and CSPC Pharmaceutical Group (1093).

Key numbers explained

• The current price of 5.57 HKD reflects the last traded value; the -0.36% price change today indicates a modest intraday decline.
• The trailing P/E ratio of 37.1 divides the current price by the last twelve months of earnings per share (0.15 CNY), showing how much investors pay per unit of recent profit.
• The forward P/E ratio of 18.2 uses expected future earnings, often interpreted as a more optimistic valuation gauge than the trailing figure.
• The dividend yield of 2.51% represents the annual dividend payment as a percentage of the current price, with 67% of earnings paid out as dividends and an ex-dividend date of 1 Sept. 2026.
• A beta of 0.63 suggests the stock has historically been less volatile than the broader market.
• The 10.6% year-over-year revenue growth on 33.7 mld. CNY trailing twelve-month revenue shows top-line expansion, while the 7.1% profit margin indicates the portion of revenue that becomes net profit.

What to watch

Investors tracking Sino Biopharm often monitor its pipeline of oncology and liver disease products, as new approvals or trial results can influence sentiment. The company's exposure to the Chinese pharmaceutical regulatory environment and healthcare policy changes is a general factor for the sector. Broader movements in the Hang Seng index and the performance of peers such as Alibaba Health (0241) or Hansoh Pharmaceutical Group (3692) can provide context. The next earnings release, scheduled for 19 Aug. 2026, is a standard catalyst for updated financials.